Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council Acute Myeloid Leukaemia Trial (MRC AML10)

1999 ◽  
Vol 106 (2) ◽  
pp. 436-444 ◽  
Author(s):  
Lynne C. Riley ◽  
Ian M. Hann ◽  
Keith Wheatley ◽  
R. F. Stevens
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Medical Research ◽  
Myeloid Leukaemia ◽  
Research Council ◽  
Medical Research Council ◽  
First Remission ◽  
Acute Myeloid

scholarly journals Results of a randomized trial in children with Acute Myeloid Leukaemia: Medical Research Council AML12 trial

2011 ◽  
Vol 155 (3) ◽  
pp. 366-376 ◽  
Author(s):  
Brenda E. S. Gibson ◽  
David K. H. Webb ◽  
Andrew J. Howman ◽  
Siebold S. N. De Graaf ◽  
Christine J. Harrison ◽  
...  
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Medical Research ◽  
Randomized Trial ◽  
Myeloid Leukaemia ◽  
Research Council ◽  
Medical Research Council ◽  
Acute Myeloid

scholarly journals Antigenic Targets for the Immunotherapy of Acute Myeloid Leukaemia

2019 ◽  
Vol 8 (2) ◽  
pp. 134 ◽  
Author(s):  
Ghazala Khan ◽  
Kim Orchard ◽  
Barbara-ann Guinn
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
High Frequency ◽  
Residual Disease ◽  
The Body ◽  
Residual Cancer ◽  
Additional Function ◽  
First Remission ◽  
Antigenic Targets ◽  
Acute Myeloid

One of the most promising approaches to preventing relapse is the stimulation of the body’s own immune system to kill residual cancer cells after conventional therapy has destroyed the bulk of the tumour. In acute myeloid leukaemia (AML), the high frequency with which patients achieve first remission, and the diffuse nature of the disease throughout the periphery, makes immunotherapy particularly appealing following induction and consolidation therapy, using chemotherapy, and where possible stem cell transplantation. Immunotherapy could be used to remove residual disease, including leukaemic stem cells from the farthest recesses of the body, reducing, if not eliminating, the prospect of relapse. The identification of novel antigens that exist at disease presentation and can act as targets for immunotherapy have also proved useful in helping us to gain a better understand of the biology that belies AML. It appears that there is an additional function of leukaemia associated antigens as biomarkers of disease state and survival. Here, we discuss these findings.

Sign in / Sign up

Export Citation Format

Share Document